SL
PTCT icon

Salomon & Ludwin’s PTC Therapeutics PTCT Stock Holding History

Salomon & Ludwin’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Sell
763
-206
-21% -$14.9K 0.01% 448
2026
Q1 		$65.7K Buy
969
+440
+83% +$31.2K 0.01% 376
2025
Q4 		$40.6K Buy
+529
New +$38.4K ﹤0.01% 477

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Salomon & Ludwin's PTCT Position: Q2 2026 in Review

Salomon & Ludwin reduced its PTC Therapeutics (PTCT) stake by 21% in Q2 2026, selling an estimated $14.9K and leaving 763 shares worth $62.1K. The position accounts for 0.01% of the portfolio, ranked #448.

Salomon & Ludwin first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $65.7K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Salomon & Ludwin held 763 shares of PTC Therapeutics worth $62.1K as of Q2 2026.
  • Salomon & Ludwin sold 206 PTC Therapeutics shares in Q2 2026, an estimated $14.9K.
  • PTC Therapeutics made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #448 holding.
  • Salomon & Ludwin first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's PTC Therapeutics position peaked at $65.7K in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.